Transmission of Hepatitis A to Patients with Hemophilia by Factor VIII Concentrates Treated with Organic Solvent and Detergent To Inactivate Viruses

Mannucci, Pier Mannuccio; Gdovin, Susan L.; Gringeri, A.; Colombo, Massimo; Mele, Alfonso; Schinaia, Nicola; Ciavarella, N.; Emerson, Suzanne U.; Purcell, Robert H.

doi:10.7326/0003-4819-120-1-199401010-00001

Cited by 230 publications

(123 citation statements)

References 0 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…Plasmaderived clotting factor concentrates, treated with the currently available virucidal method have no risk of transmitting the hepatitis B and C virus and human immunodeficiency virus [30]. However, they have the potential to transmit hepatitis A and parvovirus B19 [31,32]. While not normally a serious infection in non-immunocompromised adults, parvovirus infection of the fetus may result in hydrops fetalis and fetal death.…”

Section: (Grade C Level Iv)mentioning

confidence: 99%

The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization

et al. 2006

View full text Add to dashboard Cite

Summary. The gynaecological and obstetric management of women with inherited coagulation disorders requires close collaboration between obstetrician/ gynaecologists and haematologists. Ideally these women should be managed in a joint disciplinary clinic where expertise and facilities are available to provide comprehensive assessment of the bleeding disorder and a combined plan of management. The haematologist should arrange and interpret laboratory tests and make provision for appropriate replacement therapy. These guidelines have been provided for healthcare professionals for information and guidance and it is also intended that they are readily available for women with bleeding disorders.

show abstract

Section: (Grade C Level Iv)mentioning

confidence: 99%

The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Although HAV transmission by blood products is rare, there have been several reports on HAV outbreaks due to contaminated blood products [Mannucci et al, 1994;Robertson et al, 1998;Soucie et al, 1998;Chudy et al, 1999;Gowland et al, 2004;Heitmann et al, 2005]. To prevent contamination of blood products in The Netherlands, HAV patients are excluded from donating blood for 4 weeks after clinical symptoms are resolved, or 6 weeks in the case of contact with a HAV patient.…”

Section: Discussionmentioning

confidence: 99%

“…HAV viraemia can exceed 3 months in immunocompetent patients [Bower et al, 2000;Costa-Mattioli et al, 2002b;Sagnelli et al, 2003;Normann et al, 2004] and in one HIV-infected patient, it was detected for 256 days [Costa-Mattioli et al, 2002a]. Parenteral transmission has been reported by blood transfusion and blood products [Mannucci et al, 1994;Soucie et al, 1998] underlining the importance of detection of HAV viraemia. However, data on the duration of HAV excretion remain limited.…”

Section: Introductionmentioning

confidence: 99%

High and persistent excretion of hepatitis A virus in immunocompetent patients

et al. 2006

View full text Add to dashboard Cite

The duration and level of virus excretion in blood and faeces of patients with hepatitis A virus (HAV) infection were studied in relation to levels of alanine aminotransferase (ALT), disease severity and HAV genotype. Clinical data, blood and faeces were collected from 27 patients with acute hepatitis A (median age: 33 years) for a maximum of 26 weeks. Single blood donations from 55 other patients with acute HAV (median age: 32 years) were also used. Virus loads were quantified by competitive nested RT-PCR. HAV was excreted in faeces for a median period of 81 days after disease onset, with 50% of patients still excreting high levels at Day 36 (2 Â 10 6 -2 Â 10 8 copies/ml faeces suspension). Viraemia was detected, but not quantifiable, for a median period of 42 days. In the first 10 days of illness, higher ALT levels were correlated with higher viraemia levels. Comparison of patients infected with genotype 1a with those infected with type 1b did not differ significantly in terms of the duration of HAV excretion or jaundice. In conclusion, faecal excretion of HAV is at a high titre in the first month, perhaps making patients infectious for a longer period than assumed currently. Blood banks should be aware that viraemia may be present for more than 1 month, and genotype did not affect the duration of virus excretion or jaundice.

show abstract

“…The patients receiving clotting factor concentrate, particularly products inactivated by solvent-detergent which was ineffective against nonlipid enveloped viruses such as HAV (25)(26)(27)(28)(29)(30). In developed countries, hepatitis A vaccine is recommended for HAV seronegative people with clotting disorders, and those with CLD (31,32).…”

Section: Discussionmentioning

confidence: 99%

The Seroprevalence of Entrically Transmitted Viral Hepatitis in HCV Infected Thalassemia and Hemophilia Patients in Iran

Elizee

Alavian

Miri

et al. 2013

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Hepatitis A and E virus (HAV and HEV) infections are acute and self-limited diseases that usually spread through oral-fecal route. Also, blood transfusion as a possible route of entrically transmitted hepatitis has been suggested. Hemophilia and thalassemia patients are highly at risk of transfusion-transmissible viruses (HBV, HCV, and HIV). Any superimposed infection with other viral hepatitis (in particular hepatitis A) cause active liver failure in hemophilia and thalassemia patients. Objectives: The aim of this study is to consider seroprevalence of anti HAV and HEV antibodies (Ab) in thalassemia and hemophilia patients with chronic hepatitis C in Iran. Patients and Methods:In a cross-sectional study and under general census sampling, sera of 219 thalassemia and hemophilia patients infected with HCV were examined in Tehran Hepatitis Center (THC) between 2009 and 2010. Enzyme-linked immunisorbentassey (ELISA) was done to observe anti HAV and HEV IgG Ab. Patients were chosen from all provinces of Iran. Results: Anti-HAV IgG antibodies were observed more frequently in thalassemia patients (60/64; 93.8%) than in hemophilia patients (104/155; 67.1%, P < 0.001). The seroprevalence of both antibodies increased with age. Among thalassemia patients, there was no significant association between HAV seropositivity and other variables, but in hemophilia group, seropositive patients were significantly older than seronegative group (P < 0.05). Totally, anti HEV Ab (1/64; 1.6% thalassemia and 5/155; 3.2% hemophilia) was seropositive in six patients. There was no significant association between HEV infection and other variables in thalassemia patients, however, in hemophilia patients, HEV positive ones were significantly older than HEV negative group (P=0.01). Conclusions: Vaccination of non-immune individuals against HAV infection in high risk groups especially hemophilia and thalassemia patients is recommended. Results did not show any differences about seroprevalence of HEV among Iranian general population.

show abstract

Transmission of Hepatitis A to Patients with Hemophilia by Factor VIII Concentrates Treated with Organic Solvent and Detergent To Inactivate Viruses

Abstract: Hepatitis A was transmitted by a factor VIII concentrate treated by a virucidal method (solvent-detergent) that ineffectively inactivates nonenveloped viruses.

Cited by 230 publications

References 0 publications

The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization

The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization

High and persistent excretion of hepatitis A virus in immunocompetent patients

The Seroprevalence of Entrically Transmitted Viral Hepatitis in HCV Infected Thalassemia and Hemophilia Patients in Iran

Contact Info

Product

Resources

About